甘李药业(603087.SH)：在研药品GLR1044注射液获得药物临床试验批准

Core Viewpoint - Ganli Pharmaceutical (603087.SH) announced that its wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the investigational drug GLR1044 injection, a biosimilar to Dupilumab, aimed at treating moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription drugs [1]. Group 1 - The approval notice for GLR1044 injection has the acceptance number CXSL2500849 and the notice number 2025LP03316 [1]. - GLR1044 injection is a biosimilar of Dupilumab, which is used for treating atopic dermatitis [1].